14.27 USD
+0.03 (+0.21%)
14.2501 USD
-0.02 (-0.14%)
Taking everything into account, FOLD scores 4 out of 10 in our fundamental rating. FOLD was compared to 530 industry peers in the Biotechnology industry. FOLD has an average financial health and profitability rating. FOLD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year FOLD has reported negative net income.
FOLD had a positive operating cash flow in the past year.
In the past 5 years FOLD always reported negative net income.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -1.62%, FOLD belongs to the best of the industry, outperforming 87.92% of the companies in the same industry.
With an excellent Return On Equity value of -6.10%, FOLD belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
FOLD has a Return On Invested Capital of 4.07%. This is amongst the best in the industry. FOLD outperforms 90.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROIC | 4.07% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FOLD has a better Operating Margin (5.77%) than 89.81% of its industry peers.
The Gross Margin of FOLD (89.77%) is better than 92.08% of its industry peers.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
FOLD has more shares outstanding than it did 5 years ago.
FOLD has a better debt/assets ratio than last year.
2.2 Solvency
FOLD has an Altman-Z score of 1.04. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
FOLD has a Altman-Z score of 1.04. This is in the better half of the industry: FOLD outperforms 62.83% of its industry peers.
The Debt to FCF ratio of FOLD is 40.45, which is on the high side as it means it would take FOLD, 40.45 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 40.45, FOLD belongs to the best of the industry, outperforming 89.81% of the companies in the same industry.
A Debt/Equity ratio of 1.70 is on the high side and indicates that FOLD has dependencies on debt financing.
With a Debt to Equity ratio value of 1.70, FOLD is not doing good in the industry: 77.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Altman-Z | 1.04 |
ROIC/WACC0.44
WACC9.16%
2.3 Liquidity
FOLD has a Current Ratio of 2.99. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.99, FOLD is doing worse than 64.15% of the companies in the same industry.
A Quick Ratio of 2.09 indicates that FOLD has no problem at all paying its short term obligations.
FOLD has a worse Quick ratio (2.09) than 72.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.18%, which is quite impressive.
FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.28%.
Measured over the past years, FOLD shows a very strong growth in Revenue. The Revenue has been growing by 23.73% on average per year.
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 69.00% on average per year.
FOLD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.14% yearly.
EPS Next Y89.48%
EPS Next 2Y93.03%
EPS Next 3Y74.75%
EPS Next 5Y69%
Revenue Next Year19.4%
Revenue Next 2Y18.91%
Revenue Next 3Y18.81%
Revenue Next 5Y19.14%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
FOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 45.93, FOLD can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 91.13% of the companies listed in the same industry.
FOLD is valuated expensively when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.93 |
4.2 Price Multiples
89.43% of the companies in the same industry are more expensive than FOLD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, FOLD is valued cheaper than 90.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 454.31 | ||
| EV/EBITDA | 105.83 |
4.3 Compensation for Growth
FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 74.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y93.03%
EPS Next 3Y74.75%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
14.27
+0.03 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.15%
Inst Owner Change0%
Ins Owners0.55%
Ins Owner Change-5.53%
Market Cap4.40B
Revenue(TTM)598.70M
Net Income(TTM)-14.06M
Analysts84.71
Price Target16.26 (13.95%)
Short Float %6.57%
Short Ratio2.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.12%
Min EPS beat(2)41.73%
Max EPS beat(2)52.51%
EPS beat(4)3
Avg EPS beat(4)76.91%
Min EPS beat(4)-26.06%
Max EPS beat(4)239.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.57%
Min Revenue beat(2)0.02%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.83%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.79%
Revenue beat(12)8
Avg Revenue beat(12)-0.1%
Revenue beat(16)9
Avg Revenue beat(16)-1.08%
PT rev (1m)-0.39%
PT rev (3m)0.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.44%
EPS NY rev (1m)0%
EPS NY rev (3m)62.02%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.93 | ||
| P/S | 7.35 | ||
| P/FCF | 454.31 | ||
| P/OCF | 339.3 | ||
| P/B | 19.11 | ||
| P/tB | 246.18 | ||
| EV/EBITDA | 105.83 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.31
Fwd EY2.18%
FCF(TTM)0.03
FCFY0.22%
OCF(TTM)0.04
OCFY0.29%
SpS1.94
BVpS0.75
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROCE | 5.15% | ||
| ROIC | 4.07% | ||
| ROICexc | 6.72% | ||
| ROICexgc | 14.09% | ||
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% | ||
| FCFM | 1.62% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Debt/EBITDA | 9.31 | ||
| Cap/Depr | 43.2% | ||
| Cap/Sales | 0.55% | ||
| Interest Coverage | 0.78 | ||
| Cash Conversion | 30.81% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z | 1.04 |
F-Score5
WACC9.16%
ROIC/WACC0.44
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y89.48%
EPS Next 2Y93.03%
EPS Next 3Y74.75%
EPS Next 5Y69%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
Revenue Next Year19.4%
Revenue Next 2Y18.91%
Revenue Next 3Y18.81%
Revenue Next 5Y19.14%
EBIT growth 1Y139.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.46%
EBIT Next 3Y89.53%
EBIT Next 5YN/A
FCF growth 1Y105.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y108.46%
OCF growth 3YN/A
OCF growth 5YN/A
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the fundamental rating for FOLD stock?
ChartMill assigns a fundamental rating of 4 / 10 to FOLD.
What is the valuation status for FOLD stock?
ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.
Can you provide the profitability details for AMICUS THERAPEUTICS INC?
AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.
What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?
The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 89.48% in the next year.